Zenas BioPharma

Zenas BioPharma

生物技术研究

Waltham,MA 6,587 位关注者

Enabling patients with autoimmune diseases to reimagine life

关于我们

Zenas BioPharma (Nasdaq: ZBIO) is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative immunology-based therapies for patients in need. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas’ lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s mechanism of action and chronic dosing regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease.

网站
https://zenasbio.com/
所属行业
生物技术研究
规模
51-200 人
总部
Waltham,MA
类型
上市公司
领域
Autoimmune Diseases和Immunology

地点

  • 主要

    1000 Winter St

    Suite 1200

    US,MA,Waltham,02451

    获取路线
  • 1515 West Nanjing Road

    Level 7, Tower 2, Jing'an Kerry Center

    CN,Shanghai,Jing'an District,200041

    获取路线

Zenas BioPharma员工

动态

相似主页

查看职位

融资